The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization
Phase 4
20 Years
45 Years
20 Years
45 Years
Not Enrolling
Female
Polycystic Ovary Syndrome
Female
Polycystic Ovary Syndrome
Trial Information
The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization
Inclusion Criteria:
- diagnosed polycystic ovary syndrome patients according to Rotterdam criteria
- with hyperandrogenism and/or clinical hyperandrogenic manifestations
- no other oral contraceptives treatment for at least 3 months before this experiment
- no any other assisted reproductive therapy
- accompanied with fallopian tube and/or male factors
- normal hepato-/nephro- function
Exclusion Criteria:
- oral contraceptive pills contraindications, eg.Deep Venous Thrombosis
- smoking, drunk
- exclude other infertile factors, eg.endometriosis, abnormal thyroid function, etc.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
fertilization rate
Outcome Time Frame:
up to 2years
Safety Issue:
Yes
Authority:
China: Food and Drug Administration
Study ID:
sunyatsen8362
NCT ID:
NCT01752270
Start Date:
December 2012
Completion Date:
December 2014
Related Keywords:
- Polycystic Ovary Syndrome
- Polycystic Ovary Syndrome
Name | Location |
|---|
